This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone Sep 2026 quarter: revenue Rs 39.35 crore vs Rs 46.17 crore; after-tax loss Rs 0.57 crore
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.8 pts less than Nifty Microcap 250 and 7.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone results for the quarter ended 30 September 2026: revenue from operations was Rs 39.35 crore versus Rs 46.17 crore a year earlier; profit after tax was a Rs 0.57 crore loss versus a Rs 2.21 crore profit. Operating margin before interest, tax, depreciation and amortisation fell to 1.8 percent from 9.2 percent. Six-month operating cash flow was positive at Rs 3.46 crore; the review opinion was unmodified.
Weaker revenue and a quarterly loss point to near-term pressure, though positive six-month operating cash flow and an unmodified review offer support.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹39.35 Cr | ₹46.17 Cr | −14.8% |
| Operating profit | −₹1.13 Cr | ₹2.38 Cr | −147.3% |
| Profit after tax | −₹0.57 Cr | ₹2.21 Cr | −125.8% |
| EBITDA margin | 1.8% | 9.2% | −7.5 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.